

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)



(10) International Publication Number
WO 2023/035056 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) C07K 14/47 (2006.01)
A61K 47/69 (2017.01) C07K 16/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CA2022/051084

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

12 July 2022 (12.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,920 12 July 2021 (12.07.2021) US
63/289,016 13 December 2021 (13.12.2021) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicants: **THE HOSPITAL FOR SICK CHILDREN** [CA/CA]; 686 Bay Street, 3rd Floor, Toronto, Ontario M5G 0A4 (CA). **THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO** [CA/CA]; 100 College Street, Suite 413, Toronto, Ontario M5G 1L5 (CA).

(72) Inventors: **JULIEN, Jean-philippe**; 30 Firstbrooke Road, Toronto, Ontario M4E 2L1 (CA). **RUJAS DIEZ, Edurne**; 2-31 Fisher Street, Toronto, Ontario M6K 1V7 (CA). **TRE-ANOR, Bebhinn**; 39 Grange Avenue, Toronto, Ontario M5T 1C6 (CA). **ZHAO, Tian Tian**; 2 Weir Crescent, Toronto, Alberta M1E 3A9 (CA).

(74) Agent: **LOWTHERS, Erica L.** et al.; Aird & McBurney LP, Brookfield Place, 181 Bay Street, Suite 1800, Toronto, Ontario M5J 2T9 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS

(57) Abstract: In aspects, a self-assembled polypeptide complex comprises (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) an Fc polypeptide linked to (2) a nanocage monomer or subunit thereof, wherein the Fc polypeptide comprises a Fc chain having one or more mutations relative to a reference Fc chain of the same Ig class, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a nanocage monomer or subunit thereof.

WO 2023/035056 A1